Influence of the Molar Activity of <sup>203/212</sup>Pb-PSC-PEG<sub>2</sub>-TOC on Somatostatin Receptor Type 2-Binding and Cell Uptake
(1) Background: In neuroendocrine tumors (NETs), somatostatin receptor subtype 2 is highly expressed, which can be targeted by a radioactive ligand such as [<sup>177</sup>Lu]Lu-1,4,7,10-tetraazacyclododecane-<i>N</i>,<i>N</i>',<i>N</i>",<i...
Saved in:
Main Authors: | Marc Pretze (Author), Enrico Michler (Author), Roswitha Runge (Author), Kerstin Wetzig (Author), Katja Tietze (Author), Florian Brandt (Author), Michael K. Schultz (Author), Jörg Kotzerke (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lead-it-EAZY! GMP-compliant production of [212Pb]Pb-PSC-PEG2-TOC
by: Marc Pretze, et al.
Published: (2024) -
Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for <sup>203</sup>Pb and <sup>212</sup>Pb-Based Theranostics
by: Mengshi Li, et al.
Published: (2023) -
<sup>212</sup>Pb: Production Approaches and Targeted Therapy Applications
by: Konstantin V. Kokov, et al.
Published: (2022) -
Production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair
by: Brooke L. McNeil, et al.
Published: (2021) -
[<sup>212</sup>Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors
by: Dylan Chapeau, et al.
Published: (2023)